Nu Skin AI Stock Analysis
Want to see NUS full AI Analyst Report?
Nu Skin (NUS) AI Stock Analysis
Nu Skin
(NYSE:NUS)
Nu Skin scores near the low end of the range, driven primarily by deteriorating fundamentals: a multi-year revenue contraction that has nearly halved sales since 2021, a swing back to a sizeable net loss, and free cash flow turning negative. Technicals reinforce the caution, with the stock trading below all key moving averages and well under its 200-day average amid negative MACD momentum. Valuation offers little support given negative earnings, and the 5.3% dividend yield carries sustainability risk with free cash flow negative. The latest earnings call provides some balance, highlighting Prysm device traction, Rhyz manufacturing growth, meaningful cost reductions, and a substantially de-leveraged balance sheet with debt cut to $203.7M. However, with core customer and sales metrics still under pressure, compressing margins, and full-year reported EPS guided deeply negative, the investment case remains speculative until revenue stabilizes.
Nu Skin Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down sales across the company’s segments so you can see where growth is coming from and how diversified the business is. For Nu Skin, this reveals dependence on specific regions, product categories, or distributor channels, helps identify fast‑growing versus stagnant areas, and flags concentration or seasonal risks that could affect future top‑line momentum.
Nu Skin’s revenue mix has shifted: legacy consumer sales in Mainland China and the Americas have trended down, while Manufacturing and the Rhyz/RISE-related lines spiked in 2023–24—helping core gross margins and EPS in 2025—but Rhyz revenues pulled back in 2025 and China/Americas weakness persists, leaving top-line growth fragile. Management’s 2026 guidance is cautious and pins upside on nascent Prism IO device placements and India expansion; monetization and slower consumer adoption remain execution risks, so margin gains may outpace revenue recovery unless subscription conversion accelerates.
The FlyNu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $195.20M
- Dividend Yield
- 5.99%
- Average Volume (3M)
- 519.66K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.38
- Revenue Growth
- -15.27%
- EPS Growth
- -318.35%
- Country
- US
- Employees
- 2,800
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Nu Skin Business Overview & Revenue Model
Company Description
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageL...
How the Company Makes Money
Nu Skin makes money primarily by selling its beauty and wellness products through a direct selling network of independent brand affiliates/distributors. Revenue is recognized from product sales to customers, which in practice often occur through orde...
Nu Skin Earnings Call Summary
The call presented meaningful progress in Prysm adoption, Rhyz performance, sales-leader development, India preparation, cost restructuring, and balance-sheet management. However, these positives were balanced by ongoing core-business pressure, weaker gross and operating margins, foreign-currency headwinds, transition costs, and negative full-year reported EPS guidance. Management remained constructive about the strategic initiatives and long-term outlook, but the near-term financial picture was mixed.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter, Nu Skin expects revenue in the range of $310 million-$340 million, including an anticipated foreign currency tailwind of approximately 1%, reported earnings per share in the range of $0.05-$0.15, and adjusted earnings per share of $0.11-$0.21; it currently anticipates approximately $5 million in remaining cash-based organizational transition costs in the fourth quarter, which have been excluded from its adjusted earnings guidance. For the full year, it now expects revenue of $1.26 billion-$1.29 billion, including an anticipated foreign currency headwind of approximately 1%, annual reported earnings per share of negative $5.08 to negative $4.98, and adjusted annual earnings per share of $0.55-$0.65, excluding these non-cash items, certain other year-to-date charges, and anticipated fourth quarter organizational transition costs; after these adjustments, its guidance reflects an effective tax rate for the year of approximately 39%.
Nu Skin Financial Statement Overview
Summary
Fundamentals are weak across the board. Revenue has nearly halved since 2021 ($2.70B to $1.49B) with four straight years of double-digit declines and a further -3.9% in the trailing twelve months. Operating results swung to a loss (-2.3% operating margin) and the bottom line posted a $234M loss (-17.7% net margin). Cash generation has deteriorated sharply, with operating cash flow down to $15.2M and free cash flow turning negative at -$26.3M, which strains funding for dividends and further debt paydown. The main offsets are a resilient ~68% gross margin and a materially de-risked balance sheet, with total debt cut to $252M and debt-to-equity near 0.46x, though shareholders' equity continues to erode and return on equity is deeply negative at about -29%.
Income Statement
24NegativeBalance Sheet
48NeutralCash Flow
26Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.32B | 1.49B | 1.73B | 1.97B | 2.23B | 2.70B |
| Gross Profit | 896.94M | 1.03B | 1.18B | 1.36B | 1.59B | 2.02B |
| EBITDA | 31.29M | 262.41M | -78.83M | 204.68M | 174.97M | 319.78M |
| Net Income | -234.21M | 160.20M | -146.59M | 8.60M | 104.78M | 147.27M |
Balance Sheet | ||||||
| Total Assets | 1.09B | 1.41B | 1.47B | 1.81B | 1.82B | 1.91B |
| Cash, Cash Equivalents and Short-Term Investments | 166.64M | 239.84M | 197.99M | 267.82M | 278.51M | 354.81M |
| Total Debt | 252.42M | 364.25M | 478.23M | 607.33M | 520.52M | 503.79M |
| Total Liabilities | 540.60M | 600.07M | 817.46M | 984.50M | 923.67M | 993.71M |
| Stockholders Equity | 547.48M | 805.24M | 651.46M | 821.97M | 897.30M | 912.77M |
Cash Flow | ||||||
| Free Cash Flow | -26.26M | 46.01M | 70.16M | 60.15M | 49.01M | 72.97M |
| Operating Cash Flow | 15.20M | 80.29M | 111.74M | 118.64M | 108.06M | 141.58M |
| Investing Cash Flow | -34.83M | 170.66M | -37.96M | -134.50M | -67.08M | -88.73M |
| Financing Cash Flow | -65.75M | -202.40M | -133.18M | 10.73M | -99.50M | -104.70M |
Nu Skin Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 4.01 is below the 20-day moving average (MA) of 4.62, below the 50-day MA of 4.70, and below the 200-day MA of 5.99, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 36.34 is Neutral, neither overbought nor oversold. The STOCH value of 4.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.
Nu Skin Risk Analysis
Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksNu Skin Peers Comparison
Overall Rating
ELF68Neutral
HNST64Neutral
EL63Neutral
ODD48Neutral
YSG41Neutral- NUS38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ELF | 68Neutral | $7.01B | 77.27 | 7.39% | ― | 39.93% | 0.75% |
| HNST | 64Neutral | $556.33M | 6.56 | 40.79% | ― | -12.81% | 1040.88% |
| EL | 63Neutral | $40.70B | 107.77 | 9.28% | 1.27% | 6.23% | ― |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| ODD | 48Neutral | $917.88M | 55.62 | 4.60% | ― | -13.40% | -87.98% |
| YSG | 41Neutral | $180.10M | -5.98 | -7.20% | ― | 25.10% | 59.14% |
| NUS | 38Underperform | $189.36M | -0.80 | -34.83% | 5.99% | -15.27% | -318.35% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NUS | Nu Skin Enterprises | 4.01 | -5.28 | -56.81% | |
| EL | Estée Lauder | 110.51 | 23.57 | 27.11% | |
| ELF | e.l.f. Beauty, Inc. | 113.53 | 40.02 | 54.44% | |
| YSG | Yatsen Holding Ltd. | 1.95 | -4.89 | -71.49% | |
| HNST | Honest Company, Inc. | 4.80 | 2.22 | 86.05% | |
| ODD | ODDITY Tech Ltd. Class A | 16.73 | -22.00 | -56.80% |
Nu Skin Corporate Events
Nu Skin Announces EVP Medical Leave and Sales Oversight
NeutralOn Aug. 17, 2026, Nu Skin Enterprises, Inc. announced that Executive Vice President and President of Global Sales Justin Keisel began a medical leave of absence. Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark w...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026